Guillain-Barre Syndrome
3
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Annexon BiosciencesCA - Brisbane
2 programs2
ANX005Phase 31 trial
TanruprubartPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Annexon BiosciencesTanruprubart
Annexon BiosciencesANX005
argenxEfgartigimod Alfa-Fcab
Clinical Trials (3)
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Start: Sep 2025Est. completion: Jun 2028
Phase 3Recruiting
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
Start: Dec 2020Est. completion: Apr 2024
Phase 3Completed
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
Start: Sep 2024Est. completion: Feb 20260
Phase 2Withdrawn
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
2 companies competing in this space